May 20, 2010 (New Orleans, Louisiana) — As add-on therapy to standard treatment, the monoclonal antibody omalizumab significantly reduced exacerbations in patients with moderate to severe allergic ...

Omalizumab therapy was linked to improved inflammatory biomarkers and symptom scores after 16 weeks in patients with severe allergic asthma.

Please provide your email address to receive an email when new articles are posted on . During omalizumab treatment, volatile organic compounds and plasma lipids “strongly predicted” fewer ...

Omalizumab, alone or with allergen immunotherapy for house dust mites, may reduce daily use of inhaled corticosteroids in patients with house dust mite-sensitized mild-to-moderate allergic asthma.

Please provide your email address to receive an email when new articles are posted on . Mean serum total IgE levels began at 2,158 kU/L before increasing to 3,237 kU/L at 1 year and falling to 2,313 ...

Improved understanding of asthma endotypes, reflecting pathological processes that underlie asthma phenotypes, has informed the development of add-on biologic therapies for severe, treatment-resistant ...

Xolair, an antibody asthma drug, was recently approved for severe food allergic reactions. It is not the first biological drug to treat multiple conditions. But it is the first to treat severe food ...

Omalizumab is effective and safe for severe allergic asthma and chronic urticaria, with no significant adverse reactions reported over two decades. Remibrutinib, a Bruton tyrosine kinase inhibitor, ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an injectable asthma drug, new clinical trial findings report. In all, 36% of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Add Yahoo as a preferred source to see more of our stories on Google. In all, 36% of children treated with omalizumab (Xolair) for a year successfully ate full servings of allergy-triggering foods, ...